| 0.1592 -0.081 (-33.69%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.38 |
1-year : | 0.53 |
| Resists | First : | 0.32 |
Second : | 0.46 |
| Pivot price | 0.34 |
|||
| Supports | First : | 0.11 |
Second : | 0.09 |
| MAs | MA(5) : | 0.25 |
MA(20) : | 0.35 |
| MA(100) : | 0.57 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4.6  |
D(3) : | 2.9 |
| RSI | RSI(14): 16 |
|||
| 52-week | High : | 2.71 | Low : | 0.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GOVX ] has closed below the lower bollinger band by 13.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 102% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.25 - 0.26 | 0.26 - 0.26 |
| Low: | 0.11 - 0.11 | 0.11 - 0.12 |
| Close: | 0.16 - 0.16 | 0.16 - 0.16 |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Fri, 19 Dec 2025
GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering - Yahoo Finance
Sat, 15 Nov 2025
GeoVax Labs Earnings Call: Vaccine Progress Amid Financial Challenges - TipRanks
Fri, 14 Nov 2025
Geovax Labs Inc (GOVX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Thu, 13 Nov 2025
Earnings call transcript: GeoVax Q3 2025 shows revenue decline, stock dips - Investing.com
Fri, 26 Sep 2025
D. Boral Capital Maintains GeoVax Labs (GOVX) Buy Recommendation - Nasdaq
Wed, 20 Aug 2025
GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 11.5 (%) |
| Shares Short | 3,030 (K) |
| Shares Short P.Month | 3,140 (K) |
| EPS | -1.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.17 |
| Profit Margin | 0 % |
| Operating Margin | -761.7 % |
| Return on Assets (ttm) | -179 % |
| Return on Equity (ttm) | -377.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.66 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -0.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.93 |
| Price to Sales | 1.41 |
| Price to Cash Flow | -0.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|